Rifampicin/isoniazid/pyrazinamide
| Combination of | |
|---|---|
| Rifampicin | Rifamycin antibiotic |
| Isoniazid | Anti-tuberculosis medication |
| Pyrazinamide | Anti-tuberculosis medication |
| Clinical data | |
| Trade names | Rifater, Trifazid, others |
| AHFS/Drugs.com | FDA Professional Drug Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| KEGG | |
| (verify) | |
Rifampicin/isoniazid/pyrazinamide, also known as rifampin/isoniazid/pyrazinamide, and sold under the trade name Rifater, is a medication used to treat
Side effects are those of the underlying medications.
Rifampicin/isoniazid/pyrazinamide was approved for medical use in the United States in 1994.[3] It is on the World Health Organization's List of Essential Medicines.[4]
Medical uses
The hope of a fixed-dose combination pill is to increase the likelihood that people will take all of three medications.[5] Also, if people forget to take one or two of their drugs, they might not then develop resistance to the remaining drugs.[citation needed]
Society and culture
It is manufactured by
Aventis.[citation needed
]
See also
- Tuberculosis treatment
- Rifampicin + isoniazid + ethambutol
References
- ^ ISBN 9789241547659.
- ^ "Rifater Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 18 December 2016.
- ^ a b c d "Rifater - FDA prescribing information, side effects and uses". www.drugs.com. October 2016. Archived from the original on 21 December 2016. Retrieved 18 December 2016.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ISBN 978-0-7020-5113-5.
